← Leaderboards
Atul Varadhachary
Agennix, Inc.
$8,122,423
Attributed
$11,510,417
Total exposure
16
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,510,417 · 16
By mechanism
R44$9,017,018 · 6
R43$2,268,823 · 9
R41$224,576 · 1
Top collaborators
- Philip Breitfeld3 shared
- Stephanie Priscilla Vega3 shared
- Robert Sons2 shared
- Zebib Sielu Abraha1 shared
- Burton F Dickey1 shared
- Jacob Edward Lackovic1 shared
- Elise Marie Waldron-Young1 shared
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyInnovationBindingClinical TrialsToxicologyDesignIn VivoPharmaceutical PreparationsCostDrug KineticsPreventAnimal ModelLeadDoseTissuesBaseIn VitroMedicalAntibodiesMediatingChildPre-ClinicalModificationPlay
Grant awards (20)
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$999,997
R44 · FY2025 · CA · contact PI
Developing Scg3 Raptamers as a novel targeted therapy for wet AMD$300,016
R43 · FY2025 · EY · contact PI
Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder$320,000
R43 · FY2024 · DA · contact PI
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$84,315
R44 · FY2023 · CA · contact PI
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$999,997
R44 · FY2022 · CA · contact PI
Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation$978,343
R44 · FY2022 · OD
Expediting the Biomarker Discovery Process Through a Novel Bead-Based Aptamer Capture Platform$299,921
R43 · FY2022 · GM
Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation$993,974
R44 · FY2021 · OD
Novel inhibitor of PDE4 for the treatment of opioid use disorder$349,867
R43 · FY2020 · DA
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$998,650
R44 · FY2019 · HD · contact PI
Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients$224,771
R43 · FY2019 · DK · contact PI
Preclinical evaluation of a novel small molecule STAT inhibitor$999,993
R44 · FY2018 · AI
Innovative Delivery of siRNA across the Blood Brain Barrier$224,989
R43 · FY2018 · AG
Ureteral Stent Electromagnetic Removal (USER) Device for Pediatric Patients$224,692
R43 · FY2017 · DK · contact PI
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$224,642
R43 · FY2017 · HD · contact PI
Targeting Synaptotagmin-2 to Prevent Airway Mucus Obstruction$224,576
R41 · FY2017 · HL
Treatment of Sepsis with Talactoferrin$1,641,430
R44 · FY2008 · GM · contact PI
Treatment of Sepsis with Talactoferrin$570,399
R44 · FY2007 · GM · contact PI
Phase II Clinical Trial of Lactoferrin in Asthma$749,920
R44 · FY2005 · AI
Lactoferrin in Primate and Mouse Models of Asthma$99,925
R43 · FY2004 · AI